Yivyka (polyinosinic-polycytidylic acid/inactivated rabies virus for injection) / YS Biopharma - LARVOL DELTA

YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024 (PRNewswire) - "PIKA YS-ON-001 is designed as an immunological therapeutical agent against cancers. The Company has completed the Phase I clinical trial of PIKA YS-ON-001 in China."

Trial completion • Oncology • Solid Tumor

Dose Escalation and Cohort Expansion Study of YS-ON-001 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=31 | Completed | Sponsor: Yisheng Biopharma (Singapore) Pte. Ltd. | Recruiting ➔ Completed

Trial completion • Breast Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

YS Biopharma Announces Unaudited Financial Results for the First Quarter of Fiscal Year 2024 (PRNewswire) - "PIKA YS-ON-001 is designed as an immunological therapeutical agent against cancers. The Company has completed the enrollment of cancer patients for the Phase I clinical trial of PIKA YS-ON-001 in China. The Company expects the Phase I clinical trial will be completed by December 31, 2023."

Trial completion date • Oncology • Solid Tumor

Dose Escalation and Cohort Expansion Study of YS-ON-001 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=41 | Recruiting | Sponsor: Yisheng Biopharma (Singapore) Pte. Ltd. | Unknown status ➔ Recruiting | Trial completion date: Dec 2019 ➔ Dec 2023 | Trial primary completion date: Dec 2019 ➔ Dec 2023

Enrollment open • Metastases • Trial completion date • Trial primary completion date • Breast Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

YishengBio Raises $130 Million in Series B Funding to Accelerate Pipeline Development and Commercialization (PRNewswire) - "YishengBio Co., Ltd...announced...the closing of a US$130 million in Series B funding round....products in clinical development include YS-ON-001 for the treatment of advanced solid tumors....PIKA YS-ON-002 for solid tumor, among others, are product candidates in preclinical and discovery stages."

Commercial • Pipeline update • Oncology

Yisheng Biopharma and Tavotek Biotherapeutics announce strategic research alliance for development of YS-ON-001/002 and Tavo-301/303 combination therapy for cancer treatment (PRNewswire) - "Yisheng Biopharma Co., Ltd...and Tavotek Biotherapeutic....announced today that the companies have entered into a strategic research alliance and collaborate in the development involving their lead assets in oncology. The objective of the alliance is to co-develop a combination therapy of YS-ON-001/002 and Tavo-301/303 for cancer treatment."

Licensing / partnership

Yisheng Biopharma receives IND clearance from China NMPA to initiate clinical trial of YS-ON-001 in the treatment of advanced solid tumors (PRNewswire) - "Yisheng Biopharma Co...announced that it has received Investigational New Drug (IND) clearance from the National Medical Products Administration (NMPA) of China to initiate a clinical trial of YS-ON-001, a first-in-class immuno-oncology product for the treatment of advanced solid tumors."

Non-US regulatory